Suppr超能文献

评估终末期肝病患者多巴酚丁胺负荷超声心动图时变力反应的新指标。

New index for assessing the chronotropic response in patients with end-stage liver disease who are undergoing dobutamine stress echocardiography.

机构信息

Division of Cardiology, Department of Medicine, New Jersey Medical School, 185South Orange Avenue, Newark, NJ 07103, USA.

出版信息

Liver Transpl. 2012 Mar;18(3):355-60. doi: 10.1002/lt.22476.

Abstract

The inability to achieve 85% of the maximum predicted heart rate (MPHR) on dobutamine stress echocardiography (DSE) is defined as chronotropic incompetence and is a predictor of major cardiac events after orthotopic liver transplantation (OLT). The majority of patients with end-stage liver disease (ESLD) receive beta-blockers for the prevention of variceal bleeding. In these patients, it is impossible to determine whether chronotropic incompetence is secondary to cirrhosis-related autonomic dysfunction or is merely a beta-blocker effect. We evaluated the usefulness of the maximum achieved heart rate (MAHR) and the heart rate reserve (HRR) in the detection of chronotropic incompetence in ESLD patients on beta-blocker therapy before DSE. We also evaluated the usefulness of a new index, the modified heart rate reserve (MHRR), in diagnosing chronotropic incompetence and predicting major cardiovascular adverse events after OLT. The study population consisted of 284 ESLD patients. The mean values of MAHR (expressed as a percentage of 85% of MPHR) and HRR were significantly lower for patients on beta-blockers versus patients off beta-blockers [97.1% versus 101.6% (t = 5.01, P < 0.001) and 71.7% versus 77.3% (t = 4.03, P < 0.001), respectively], whereas the values of MHRR were similar in patients on beta-blockers and patients off beta-blockers [102.3% versus 102.1% (t = 0.04, P = 0.97)]. A regression analysis showed a significant association of MAHR (P < 0.001) and HRR (P < 0.001) with beta-blockers, whereas MHRR was not associated with beta-blocker treatment (P = 0.92). MAHR and HRR were found to have no value for diagnosing chronotropic incompetence in ESLD patients. MHRR was not affected by beta-blocker therapy. Patients who developed heart failure (HF) and myocardial infarction (MI) after OLT had significantly lower MHRR values according to pretransplant DSE. MHRR was significantly associated with the subsequent development of HF (P = 0.01) and MI (P = 0.01) after OLT. MHRR may be useful for the determination of the target heart rate for stress testing, the diagnosis of chronotropic incompetence, and the prediction of adverse cardiac events after OLT.

摘要

多巴酚丁胺超声心动图检查时无法达到最大预测心率(MPHR)的 85%被定义为变时功能不全,是原位肝移植(OLT)后发生主要心脏事件的预测因素。大多数终末期肝病(ESLD)患者接受β受体阻滞剂预防静脉曲张出血。在这些患者中,无法确定变时功能不全是继发于肝硬化相关自主神经功能障碍还是仅仅是β受体阻滞剂的作用。我们评估了在多巴酚丁胺超声心动图检查前接受β受体阻滞剂治疗的 ESLD 患者中最大心率(MAHR)和心率储备(HRR)在检测变时功能不全中的有用性。我们还评估了新指标改良心率储备(MHRR)在诊断变时功能不全和预测 OLT 后主要心血管不良事件中的作用。研究人群包括 284 例 ESLD 患者。与未使用β受体阻滞剂的患者相比,使用β受体阻滞剂的患者 MAHR(以 MPHR 的 85%表示)和 HRR 的平均值明显较低[97.1%比 101.6%(t=5.01,P<0.001)和 71.7%比 77.3%(t=4.03,P<0.001)],而 MHRR 值在使用β受体阻滞剂和未使用β受体阻滞剂的患者之间相似[102.3%比 102.1%(t=0.04,P=0.97)]。回归分析显示 MAHR(P<0.001)和 HRR(P<0.001)与β受体阻滞剂显著相关,而 MHRR 与β受体阻滞剂治疗无关(P=0.92)。MAHR 和 HRR 对诊断 ESLD 患者的变时功能不全没有价值。MHRR 不受β受体阻滞剂治疗的影响。OLT 后发生心力衰竭(HF)和心肌梗死(MI)的患者,根据移植前 DSE,其 MHRR 值明显较低。MHRR 与 OLT 后 HF(P=0.01)和 MI(P=0.01)的发生显著相关。MHRR 可能有助于确定应激试验的目标心率、变时功能不全的诊断以及 OLT 后不良心脏事件的预测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验